拓扑替康耐药卵巢癌症细胞系中TGFBI基因和蛋白的表达。

IF 2.5 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in medical sciences Pub Date : 2023-09-01 DOI:10.1016/j.advms.2023.09.013

Karolina Wojtowicz , Monika Świerczewska , Michał Nowicki , Radosław Januchowski

{"title":"拓扑替康耐药卵巢癌症细胞系中TGFBI基因和蛋白的表达。","authors":"Karolina Wojtowicz , Monika Świerczewska , Michał Nowicki , Radosław Januchowski","doi":"10.1016/j.advms.2023.09.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>The primary limiting factor in achieving cures for patients with cancer, particularly ovarian cancer, is drug resistance. The mechanisms of drug resistance of cancer cells during chemotherapy may include compounds of the extracellular matrix, such as the transforming growth factor-beta-induced protein (TGFBI). In this study, we aimed to analyze the <em>TGFBI</em> gene and protein expression in different sensitive and drug-resistant ovarian cancer cell lines, as well as test if TGFBI can be involved in the response to topotecan (TOP) at the very early stages of treatment.</p></div><div><h3>Materials and methods</h3><p>In this study, we conducted a detailed analysis of TGFBI expression in different ovarian cancer cell lines (A2780, A2780TR1, A2780TR2, W1, W1TR, SKOV-3, PEA1, PEA2 and PEO23). The level of <em>TGFBI</em> mRNA (QPCR), intracellular and extracellular protein (Western blot analysis) were assessed in this study.</p></div><div><h3>Results</h3><p>We observed upregulation of <em>TGFBI</em> mRNA in drug-resistant cell lines and estrogen-receptor positive cell lines, which was supported by overexpression of both intracellular and extracellular TGFBI protein. We also showed the <em>TGFBI</em> expression after a short period of treatment of sensitive ovarian cancer cell lines with TOP.</p></div><div><h3>Conclusion</h3><p>The expression of TGFBI in ovarian cancer cell lines suggests its role in the development of drug resistance.</p></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"68 2","pages":"Pages 379-385"},"PeriodicalIF":2.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines\",\"authors\":\"Karolina Wojtowicz , Monika Świerczewska , Michał Nowicki , Radosław Januchowski\",\"doi\":\"10.1016/j.advms.2023.09.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>The primary limiting factor in achieving cures for patients with cancer, particularly ovarian cancer, is drug resistance. The mechanisms of drug resistance of cancer cells during chemotherapy may include compounds of the extracellular matrix, such as the transforming growth factor-beta-induced protein (TGFBI). In this study, we aimed to analyze the <em>TGFBI</em> gene and protein expression in different sensitive and drug-resistant ovarian cancer cell lines, as well as test if TGFBI can be involved in the response to topotecan (TOP) at the very early stages of treatment.</p></div><div><h3>Materials and methods</h3><p>In this study, we conducted a detailed analysis of TGFBI expression in different ovarian cancer cell lines (A2780, A2780TR1, A2780TR2, W1, W1TR, SKOV-3, PEA1, PEA2 and PEO23). The level of <em>TGFBI</em> mRNA (QPCR), intracellular and extracellular protein (Western blot analysis) were assessed in this study.</p></div><div><h3>Results</h3><p>We observed upregulation of <em>TGFBI</em> mRNA in drug-resistant cell lines and estrogen-receptor positive cell lines, which was supported by overexpression of both intracellular and extracellular TGFBI protein. We also showed the <em>TGFBI</em> expression after a short period of treatment of sensitive ovarian cancer cell lines with TOP.</p></div><div><h3>Conclusion</h3><p>The expression of TGFBI in ovarian cancer cell lines suggests its role in the development of drug resistance.</p></div>\",\"PeriodicalId\":7347,\"journal\":{\"name\":\"Advances in medical sciences\",\"volume\":\"68 2\",\"pages\":\"Pages 379-385\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in medical sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1896112623000408\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in medical sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1896112623000408","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：癌症，特别是癌症患者获得治疗的主要限制因素是耐药性。癌症细胞在化疗期间的耐药性机制可能包括细胞外基质化合物，如转化生长因子-β诱导蛋白（TGFBI）。在本研究中，我们旨在分析TGFBI基因和蛋白在不同敏感和耐药卵巢癌症细胞系中的表达，并测试TGFBI是否可以参与治疗早期对拓扑替康（TOP）的反应。材料和方法：在本研究中，我们对不同卵巢癌症细胞系（A2780、A2780TR1、A2780 TR2、W1、W1TR、SKOV-3、PEA1、PEA2和PEO23）中TGFBI的表达进行了详细分析。本研究评估了TGFBI mRNA（QPCR）、细胞内和细胞外蛋白（Western印迹分析）的水平。结果：我们在耐药细胞系和雌激素受体阳性细胞系中观察到TGFBI mRNA的上调，这得到了细胞内和细胞外TGFBI蛋白过度表达的支持。我们还显示了用TOP短期治疗敏感的卵巢癌症细胞系后TGFBI的表达。结论：TGFBI在卵巢癌症细胞系中的表达表明其在耐药性发展中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines

Purpose

The primary limiting factor in achieving cures for patients with cancer, particularly ovarian cancer, is drug resistance. The mechanisms of drug resistance of cancer cells during chemotherapy may include compounds of the extracellular matrix, such as the transforming growth factor-beta-induced protein (TGFBI). In this study, we aimed to analyze the TGFBI gene and protein expression in different sensitive and drug-resistant ovarian cancer cell lines, as well as test if TGFBI can be involved in the response to topotecan (TOP) at the very early stages of treatment.

Materials and methods

In this study, we conducted a detailed analysis of TGFBI expression in different ovarian cancer cell lines (A2780, A2780TR1, A2780TR2, W1, W1TR, SKOV-3, PEA1, PEA2 and PEO23). The level of TGFBI mRNA (QPCR), intracellular and extracellular protein (Western blot analysis) were assessed in this study.

Results

We observed upregulation of TGFBI mRNA in drug-resistant cell lines and estrogen-receptor positive cell lines, which was supported by overexpression of both intracellular and extracellular TGFBI protein. We also showed the TGFBI expression after a short period of treatment of sensitive ovarian cancer cell lines with TOP.

Conclusion

The expression of TGFBI in ovarian cancer cell lines suggests its role in the development of drug resistance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances in medical sciences 医学-医学：研究与实验

CiteScore

5.00

自引率

0.00%

发文量

审稿时长

25 days

期刊介绍： Advances in Medical Sciences is an international, peer-reviewed journal that welcomes original research articles and reviews on current advances in life sciences, preclinical and clinical medicine, and related disciplines. The Journal’s primary aim is to make every effort to contribute to progress in medical sciences. The strive is to bridge laboratory and clinical settings with cutting edge research findings and new developments. Advances in Medical Sciences publishes articles which bring novel insights into diagnostic and molecular imaging, offering essential prior knowledge for diagnosis and treatment indispensable in all areas of medical sciences. It also publishes articles on pathological sciences giving foundation knowledge on the overall study of human diseases. Through its publications Advances in Medical Sciences also stresses the importance of pharmaceutical sciences as a rapidly and ever expanding area of research on drug design, development, action and evaluation contributing significantly to a variety of scientific disciplines. The journal welcomes submissions from the following disciplines: General and internal medicine, Cancer research, Genetics, Endocrinology, Gastroenterology, Cardiology and Cardiovascular Medicine, Immunology and Allergy, Pathology and Forensic Medicine, Cell and molecular Biology, Haematology, Biochemistry, Clinical and Experimental Pathology.